 | Up a level |
2015
Thomas, M., Schuler, M., Potzner, M., Szczudlo, T., Sutradhar, S., Yovine, A. and Wolf, J. (2015). Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases. Oncol. Res. Treat., 38. S. 270 - 271. BASEL: KARGER. ISSN 2296-5262
Wolf, J., Schneider, C-P, Potzner, M., Arratia, Cazorla P., Shen, J., Branle, F. and von Pawel, J. (2015). The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges. Oncol. Res. Treat., 38. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262